IRON

SEC source: 0001209191-23-010679 · doc4.xml · nonDerivative · entry 1

AI DMI LLC · CIK 0001890993 · 10% owner

Access Industries Holdings LLC · CIK 0001391297 · 10% owner

ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner

Blavatnik Len · CIK 0001326628 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,141,759

F1 · ownership.direct: The securities reported are held directly by AI DMI LLC ("AI DMI") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, AIM controls AIH, and AIH indirectly controls all of the outstanding voting interests in AI DMI LLC. Each of the reporting persons (other than AI DMI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

SEC source: 0000899243-23-000460 · doc4.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,139,507

F1 · kind: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · kind: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F1 · price: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · price: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F5 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F6 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, Genesis GP, GP VI, and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VI, and GP VIII have designated a representative, Mona Ashiya ("Ashiya"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-000460 · doc4.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 736,558

F1 · kind: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · kind: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F1 · price: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · price: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F6 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, Genesis GP, GP VI, and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VI, and GP VIII have designated a representative, Mona Ashiya ("Ashiya"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-000460 · doc4.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 582,622

F7 · kind: On December 29, 2022, Gemini effected a 1-for-10 reverse stock split of its common stock.

F7 · price: On December 29, 2022, Gemini effected a 1-for-10 reverse stock split of its common stock.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F6 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, Genesis GP, GP VI, and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VI, and GP VIII have designated a representative, Mona Ashiya ("Ashiya"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-000460 · doc4.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 284,876

F1 · kind: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · kind: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F1 · price: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · price: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.

F6 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, Genesis GP, GP VI, and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VI, and GP VIII have designated a representative, Mona Ashiya ("Ashiya"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-23-000461 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 955,156

F1 · kind: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F1 · price: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · price: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000899243-23-000461 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,237,303

F1 · kind: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F1 · price: Gemini Therapeutics, Inc. (" Gemini"), and Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) ("Disc"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), on August 9, 2022, pursuant to which, among other matters, a direct, wholly owned subsidiary of Gemini, Gemstone Merger Sub, Inc. ("Merger Sub"), merged with and into Disc, with Disc surviving as a wholly owned subsidiary of Gemini, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The merger closed on on December 29, 2022. Following the effectiveness of the merger on December 29, 2022, the surviving corporation changed its name from Gemini to Disc Medicine, Inc. (the "Issuer").

F2 · price: (Continued from footnote 1) Upon the closing of the merger, each share of Disc common stock (after giving effect to the conversion of each share of Disc's preferred stock into Disc common stock and including all such shares that are converted into Disc common stock) was converted into the right to receive a number of shares of Gemini common stock equal to an exchange ratio of 0.1096.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000899243-23-000459 · doc4.xml · derivative · entry 1

Bitterman Kevin · CIK 0001591747 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000899243-23-000455 · doc4.xml · derivative · entry 1

Ashiya Mona · CIK 0001794070 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP.

SEC source: 0000899243-23-000320 · doc4.xml · derivative · entry 1

Nicholson Donald William · CIK 0001814617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000318 · doc4.xml · derivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000314 · doc4.xml · derivative · entry 1

MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,847

Underlying: Common Stock · 33,847 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000309 · doc4.xml · derivative · entry 1

Chin Mark · CIK 0001734389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000307 · doc4.xml · derivative · entry 1

Khara Rahul · CIK 0001951850 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,770

Underlying: Common Stock · 28,770 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000306 · doc4.xml · derivative · entry 1

Yu Jonathan Yen-Wen · CIK 0001951849 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,847

Underlying: Common Stock · 33,847 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000301 · doc4.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000299 · doc4.xml · derivative · entry 1

Bryce Joanne · CIK 0001951845 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,847

Underlying: Common Stock · 33,847 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000298 · doc4.xml · derivative · entry 1

Savage William Jacob · CIK 0001951852 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,924

Underlying: Common Stock · 38,924 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000297 · doc4.xml · derivative · entry 1

Quisel John D · CIK 0001586788 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,002

Underlying: Common Stock · 132,002 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000296 · doc4.xml · derivative · entry 1

Backstrom Jay T. · CIK 0001796398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-000295 · doc4.xml · derivative · entry 1

White William Richard · CIK 0001778739 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-12-28

F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001567619-22-018854 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,500

F2 · price: The shares were sold in multiple transactions at $2.09.

SEC source: 0001209191-22-033719 · doc4.xml · nonDerivative · entry 1

Piekos Brian · CIK 0001815308 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,615

F1 · kind: These shares were acquired under the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan ("ESPP").

F2 · price: In accordance with the terms of the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022.

SEC source: 0001567619-22-008485 · doc1.xml · nonDerivative · entry 4

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Holding of BML Investment Partners, L.P.(1)

Disclosed balance after: 5,000,000

F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.45 to $1.60. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F1 · ownership.nature: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-008485 · doc1.xml · nonDerivative · entry 3

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Holding of BML Investment Partners, L.P.(1)

Disclosed balance after: 4,808,231

F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.35 to $1.45. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F1 · ownership.nature: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-008485 · doc1.xml · nonDerivative · entry 1

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,000

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.355 to $1.40. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001567619-22-008485 · doc1.xml · nonDerivative · entry 2

Leonard Braden Michael · CIK 0001373603 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Holding of BML Investment Partners, L.P.(1)

Disclosed balance after: 4,604,487

F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.3496 to $1.35. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F1 · ownership.nature: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-003268 · doc4.xml · derivative · entry 1

Piekos Brian · CIK 0001815308 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,876

Underlying: Common Stock · 280,876 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.

F2 · derivative.exercise_date: These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant.

F2 · derivative.expiration_date: These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant.

SEC source: 0001209191-22-001634 · doc4.xml · derivative · entry 1

Meyenburg Jason Patrick · CIK 0001709008 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,600

Underlying: Common Stock · 123,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.

F2 · derivative.exercise_date: These Restricted Stock Units shall vest in accordance with certain performance based metrics.

F2 · derivative.expiration_date: These Restricted Stock Units shall vest in accordance with certain performance based metrics.

SEC source: 0001209191-22-001628 · doc4.xml · derivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director · Executive Chair of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 793,274

Underlying: Common Stock · 793,274 shares

Expires 2032-01-02

F1 · derivative.exercise_date: 50% of the Option Shares shall become exercisable on August 5, 2022 and the remaining 50% of the Option Shares shall become exercisable on August 5, 2023.

SEC source: 0000899243-21-044718 · doc4.xml · derivative · entry 2

GEMAYEL GEORGES · CIK 0001256088 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2031-11-14

F2 · derivative.exercise_date: 100% of the option shall vest on the earlier of (a) the one-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0000899243-21-044718 · doc4.xml · derivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,514

Underlying: Common Stock · 23,514 shares

Expires 2031-11-14

F1 · derivative.exercise_date: 100% of the option shall vest on August 5, 2022 so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0000899243-21-040808 · doc4.xml · derivative · entry 1

Piekos Brian · CIK 0001815308 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,720

Underlying: Common Stock · 90,720 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.

F2 · derivative.exercise_date: Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone.

F2 · derivative.expiration_date: Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone.

SEC source: 0000899243-21-039456 · doc4.xml · derivative · entry 1

Rhodes Jason P · CIK 0001577014 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2031-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-21-039457 · doc4.xml · derivative · entry 4

Tananbaum James B. · CIK 0001581754 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2021-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0000899243-21-039455 · doc4.xml · derivative · entry 1

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2031-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

SEC source: 0000899243-21-039454 · doc4.xml · derivative · entry 1

Ong Tuyen · CIK 0001673178 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2031-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0000899243-21-039453 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,245

Underlying: Common Stock · 17,245 shares

Expires 2031-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0001209191-22-017669 · doc4a.xml · derivative · entry 1

Ong Tuyen · CIK 0001673178 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2031-10-03

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

SEC source: 0001209191-22-017668 · doc4a.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires not disclosed

F1 · derivative.exercise_price: This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 ("Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person.

F1 · derivative.exercise_date: This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 ("Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person.

F1 · derivative.expiration_date: This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 ("Original Form 4"). The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person.

SEC source: 0000899243-21-019763 · doc4.xml · nonDerivative · entry 1

Piekos Brian · CIK 0001815308 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,655

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-019762 · doc4.xml · nonDerivative · entry 1

Meyenburg Jason Patrick · CIK 0001709008 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

SEC source: 0001213900-21-024226 · ownership.xml · derivative · entry 1

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,466

Underlying: Common Stock · 45,466 shares

Expires 2031-04-28

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of three years from the Vesting Start Date, April 29, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting in eight quarterly installments thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-024225 · ownership.xml · derivative · entry 1

Strapps Walter · CIK 0001849041 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2031-04-29

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of three years from the Grant Date, April 28, 2021, with 25% vesting on the Grant Date, and the remainder vesting in equal installments over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-021524 · ownership.xml · derivative · entry 1

Piekos Brian · CIK 0001815308 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,734

Underlying: Common Stock · 377,734 shares

Expires 2031-04-11

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-021520 · ownership.xml · derivative · entry 1

Barone Samuel B. · CIK 0001614995 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,212

Underlying: Common Stock · 255,212 shares

Expires 2031-04-11

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-015397 · ownership.xml · derivative · entry 1

Ong Tuyen · CIK 0001673178 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-015393 · ownership.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001209191-22-017671 · doc4a.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,529

Underlying: Common Stock · 17,529 shares

Expires 2031-03-11

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-013236 · ownership.xml · derivative · entry 1

Strapps Walter · CIK 0001849041 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,133

Underlying: Common Stock · 99,133 shares

Expires 2031-02-28

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, March 1, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.